# Nature-inspired metaheuristics for optimizing dose-finding and computationally challenging clinical trial designs

**Authors:** Weng Kee Wong, Yevgen Ryeznik, Oleksandr Sverdlov, Ping-Yang Chen, Xinying Fang, Ray-Bing Chen, Shouhao Zhou, J Jack Lee

PMC · DOI: 10.1177/17407745251346396 · Clinical Trials (London, England) · 2025-07-12

## TL;DR

This paper explores using nature-inspired optimization algorithms to improve clinical trial designs, particularly for finding optimal drug doses while balancing safety and effectiveness.

## Contribution

The paper introduces the use of particle swarm optimization for dose-finding in clinical trials, improving safety and accuracy under complex constraints.

## Key findings

- PSO algorithm effectively identifies optimal biological doses while protecting patients from excessive toxicity.
- Metaheuristics enable more flexible and powerful phase II trial designs with multiple stages.
- The approach outperforms existing methods in accuracy and computational efficiency for complex trial settings.

## Abstract

Metaheuristics are commonly used in computer science and engineering to solve optimization problems, but their potential applications in clinical trial design have remained largely unexplored. This article provides a brief overview of metaheuristics and reviews their limited use in clinical trial settings. We focus on nature-inspired metaheuristics and apply one of its exemplary algorithms, the particle swarm optimization (PSO) algorithm, to find phase I/II designs that jointly consider toxicity and efficacy. As a specific application, we demonstrate the utility of PSO in designing optimal dose-finding studies to estimate the optimal biological dose (OBD) for a continuation-ratio model with four parameters under multiple constraints. Our design improves existing designs by protecting patients from receiving doses higher than the unknown maximum tolerated dose and ensuring that the OBD is estimated with high accuracy. In addition, we show the effectiveness of metaheuristics in addressing more computationally challenging design problems by extending Simon’s phase II designs to more than two stages and finding more flexible Bayesian optimal phase II designs with enhanced power.

## Full-text entities

- **Diseases:** toxicity (MESH:D064420)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12318163/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12318163/full.md

## References

47 references — full list in the complete paper: https://tomesphere.com/paper/PMC12318163/full.md

---
Source: https://tomesphere.com/paper/PMC12318163